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Abstract. There is limited information describing species related pharmacogenetic differences in animals.
Despite the lack of genetic information in veterinary medicine, breed speciﬁc responses to endogenous
and exogenous substances have been reported across many species. This ﬁnding underscores the
importance of obtaining insight into the genotypic and phenotypic variation present across breeds. This
article provides a summary of the literature pertaining to canine breed differences in physiology, drug
response, drug pharmacokinetics, and metabolic idiosyncrasies. The existing knowledge of pedigrees and
the known phenotypes and genotypes of dogs provides important information for determining mode of
inheritance, penetration, and other major characteristics of heritable traits. Understanding these breed
differences will improve canine population predictions (for canine drug products) and may be of value
when extrapolating toxicology data from dogs to humans.
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INTRODUCTION
There is a limited body of work describing species
related pharmacogenetic differences in animals, despite the
explosion of pharmacogenetic information in humans (see
AAPS Pharmacogenetics/Pharmacogenomics Virtual Journal,
http://www.aapsj.org/theme_issues/virtual/index.asp). Pub-
lished literature conﬁrms that there is little difference
between human and veterinary species in regard to the
magnitude of inter-subject variability in drug pharmacokinet-
ics and pharmacodynamics. Despite the lack of genetic
information in veterinary medicine, breed speciﬁc differences
in response to endogenous and exogenous substances have
been reported across a range of species, including cattle (1),
sheep (2), chickens (3), pigs (4), and dogs (as described
below).
Whether the goal is to maximize the human prediction
potential of data obtained in dogs or to improve our ability to
extrapolate limited canine safety and effectiveness data to the
entire canine population, it is important to appreciate the
genotypic and phenotypic variation that is present across
breeds. With this objective in mind, the Animal Pharmaceu-
tics and Technology Focus Group of the American Associa-
tion of Pharmaceutical Scientists (AAPS) launched a working
group to examine the breed-speciﬁc idiosyncrasies in physi-
ology and metabolism that could inﬂuence both the use of
dogs as an animal model for human drug research and the
development of pharmaceuticals for use in dogs. This working
group provided discussion and articles that were used in the
development of a database that focused on phenotypic and
metabolic differences observed across breeds of dogs.
This article summarizes the published work on canine
breed differences in physiology and pharmacology. It reﬂects
an effort to establish a library of published literature that
describes differences in drug response, drug pharmacokinet-
ics, or metabolic idiosyncrasies that can lead to either
inconsistencies in the results of studies conducted in dogs
(across breeds) or failure to adequately predict breed-speciﬁc
differences that could lead to safety or effectiveness concerns
when products are administered to dogs.
BREED OVERVIEW
A breed is deﬁned as a group of organisms having
common ancestors and certain distinguishable characteristics
developed by artiﬁcial selection and maintained by controlled
propagation (5). Across domestic animal species, some of the
greatest physical diversity may be found across breeds of dog.
For example, canine body weights range from approximately
4 lb for the Chihuahua to over 200 lb for the Great Dane, St.
Bernard, and Irish Wolfhound. Recently, a portion of the size
difference between breeds of dogs has been traced to a single
gene encoding for insulin-like growth factor 1 (IGF-1). A
single IGF-1 single-nucleotide polymorphism haplotype was
found to be common to all small breeds and practically absent
from giant breeds (6).
There are over 400 breeds of dogs recognized worldwide
and 156 breeds recognized by the American Kennel Club
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Although most modern canine breeds have existed for
fewer than 400 years, each has its own distinctive genetic
characteristics. Fixation of the phenotypic appearance and the
mating of closely related individuals have resulted in breed-
speciﬁc disease patterns and great variations in life expectancy.
This size differences between breeds can also be associated
with deleterious physical consequences. In a study of over
52,000 dogs, the likelihood of reaching 10 years of age was
greater than 85% for Poodles, 75% for mongrels and Beagles,
and only 30% for Bernese Mountain Dogs (9). Of course, size
is only one of many factors associated with the average life
span of dogs. Unrelated to their size, the shortened average
lifespan of Cavalier King Charles Spaniels, Irish Wolfhounds,
and Great Danes, for instance is due to a high risk of
cardiomyopathies (10). Indeed, many breeds display an
excess of particular disease as has been cataloged by Sargan
and colleagues (11).
With this great magnitude of genetic diversity, it is not
surprising that there are both metabolic and physiologic
idiosyncrasies that can inﬂuence not only the propensity for
certain disease conditions, but also drug pharmacokinetics
and the characteristics of responses to xenobiotics.
GENETICS AND BREED
Despite the advent of modern genetic methods, pedigree
analysis remains an essential, and in some cases the only
technique available to analyze the inheritance of genetic
defects or desirable traits. Coupling this existing knowledge
of pedigrees with known phenotypes and genotypes of the
dog provides important information for determining mode of
inheritance, penetration, and other major characteristics of a
heritable trait. However, for dogs that do not have their
pedigree information available, Parker et al. (7,8) revealed
that one can identify the diversity of breeds, or lack thereof,
in an individual dog through DNA analysis.
The genetic sequence of the dog, from one female Boxer,
became publicly available in July, 2004 (12). The draft
sequence can be accessed online (13–15). The University of
California, Santa Cruz published more information on the
search capabilities of the sequence and annotation data in the
genome databases (16). Just as important is the 1.5× sequence
of the standard poodle, which became available in 2003 and
provided an additional set of chromosomes for evaluation
(17).
Based upon work conducted, at the Fred Hutchinson
Cancer Research Center in Seattle WA, dogs can be correctly
assigned to their breed of origin 99% of the time through the
use of DNA analysis (18). This breed identiﬁcation is based
on the differences in DNA markers between breeds and
microsatellite loci (8). This information can be used in turn to
determine if a dog may be predisposed to certain genetically
based diseases. A genetic test is commercially available
through Mars Veterinary (19). Knowledge of breed predispo-
sition can be especially important if a molecular test is not
available for the trait of interest.
Other uses for DNA markers may include the identiﬁ-
cation of genetic diseases or metabolic differences that can be
localized within related groups of breeds. Alternatively,
genotyping could identify individuals with speciﬁc genetic
mutations that can affect therapeutic decisions. Searchable
databases of canine markers and chromosome maps are
available on the Canine Genetics Research Projects page at
Fig. 1. Dog History Tree. [Reproduced with permission from Mars Veterinary]
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by chromosome and breed is available on-line (21). An
updated database is available at the National Human Genome
Research Institute (NHGRI) and at the Broad Institute
(21,22). The ultimate goal is to go beyond markers and have
a complete genome map that permits the identiﬁcation of traits
directly from the DNA code of an individual animal.
SIMILARITIES BETWEEN HUMAN AND CANINE
GENOME
Interest in the canine genome project is sparked by the
insight it provides into the relationship between human
genetics and disease. In their 2005 review of the canine
genome, Ostrander and Wayne describe how understanding
genetic diseases in dogs greatly impacts the understanding of
important diseases in both dogs and humans (23). Among the
many disease conditions being investigated, cancer, deafness,
heart disease, blindness, and epilepsy are examples of
conditions well suited for genetic mapping in dogs (24).
Comparisons between the domesticated dog and human
genomes reveal distinct differences as well as some important
similarities (Tables I and II).
While the information presented in Tables I and II is
based upon an analysis of the complete genome of a single
dog (Boxer), a partial genome analysis of a male Standard
Poodle revealed similar ﬁndings in the comparison of the
human and dog genomes (17). Finally, when examining the
base pairs comprising a representative sample of canine
genes, compositional correlations between the species are
also identiﬁed (25). Therefore, the differences between the
human and canine genomes exist primarily at a superﬁcial
level, and a detailed analysis of the genomes reveals that the
two genomes have many signiﬁcant similarities.
The similarities of the genomes are also reﬂected in the
identiﬁcation of genetic defects associated with disease. Over
360 genetic disorders observed in humans have also been
identiﬁed in dogs. Almost all of these defects were ﬁrst
identiﬁed in humans and involve a mutation of the same or an
analogous gene in the dog (26).
An understanding of the canine genome, together with
our knowledge of disease incidence within a breed, facilitates
an understanding of the genetic basis of disease within the
human population. Points to consider are:
1. Does disease incidence differ by breed?
2. Do we see a breed-related difference in the frequency
of a speciﬁc mutation of a gene(s) potentially related
to the disease?
3. Can we establish this defect(s) as the cause of the
disease in dogs?
4. Is there a correlation between the disease as ex-
pressed in humans and dogs?
5. Is there an analogous gene in humans?
In addition to the genetic similarities identiﬁed between
humans and dogs, the modern dog offers key advantages over
other animal systems because of constraints placed on its
diversity. In addition, catastrophic events such as the two world
wars and the American depression have reduced the effective
breedingstock.Therefore,thepurebred dogsoftoday represent
a limited genetic pool, with disease predispositions that derive
from one or a small number of recent genetic founders (24).
From a population perspective, the mating of closely
related individuals to propagate selected characteristics has
resulted in a greater degree of genetic diversity between dog
breeds as compared to that observed between human ethnic
groups. For example, the tendency towards speciﬁc metabolic
diseases appears to follow breed lines. However, unlike
humans where inborn errors of metabolism are generally
attributable to many different mutations in a particular gene,
in dogs (and cats), the same mutation is generally responsible
for the speciﬁc disease within a particular breed (27). While
only 5% to 10% of human genetic variation has been shown
to be associated with populations or races, 27% of genetic
variation in dogs is associated with differences in breed (7).
Since at least 50% of the deﬁned hereditary diseases in dogs
have signiﬁcant breed-speciﬁc aggregations (26), there is a
greater likelihood of identifying genetic links in humans by
utilizing known breed differences in dogs.
GENETICALLY RELATED DISEASES IN THE DOG
Breed differences in the incidence of speciﬁc diseases are
well recognized in veterinary medicine (28).
There are over 370 inherited disorders described in the
purebred dog population. Of the identiﬁed disorders in which
the mode of inheritance is known with reasonable certainty,
more than half are identiﬁed as autosomal recessive (26). In
contrast, some important heritable defects, such as hip
dysplasia and osteoarthritis in dogs, involve multiple genes
and environmental inﬂuences (29). The predominance of
diseases associated with autosomal recessive traits can be
Table I. Differences in Human and Canine Genome (12)
Differences
Canine Human
Diploid number 78 46
Number of base pairs (Gb) 2.4 2.9
Predicted number of genes 19,300 22,000
Gene duplications in humans lineage occurs approximately twice as
frequently as that observed in the canine lineage
Table II. Similarities in Human and Canine Genome (12)
Similarities
Ninety-four percent of the dog genome is in the same order
within individual chromosomes (synteny) as seen in the
human, mouse, and rat
The majority of the predicted genes in the canine genome
are homologues of known human genes
The disparity between the numbers of genes in humans and dogs
may become smaller as the techniques for identifying
functional genes from the predicted genes improve
Although the number and frequency of gene duplications speciﬁc
to each lineage differ, the duplications occur in similar gene
clusters, including genes involved in adaptive immunity,
innate immunity, chemosensation, and reproduction
112 Fleischer et al.attributed to the breeding and selection patterns used by
breeders to propagate speciﬁc traits.
Several databases on heritable diseases and traits in dogs
and other species are available on the internet:
& Online Mendelian Inheritance in Animals (OMIA) is a
databaseofgenes,inheriteddisordersandtraitsinmore
than 135 animal species (other than human and mouse)
(30). The database contains textual information and
references, as well as links to relevant PubMed and
gene records at the National Center for Biotechnology
Information (NCBI). The NCBI also has a dedicated
webpage to dog genome resources (31).
& The Inherited Diseases in Dogs (IDID) web site
contains a database of diseases/conditions of pure bred
dogs which are likely to be transmitted completely or
partially through a genetic mechanism (11,32). The site
also lists the testing agencies (UK and USA) where
DNA testing is available for a given disease.
& The Canine Inherited Disorders Database (CIDD)
was developed to reduce the incidence of inherited
disorders in dogs by providing information to owners
and breeders, and to facilitate the best management
possible of these conditions by providing current
information to veterinarians (33). The database is
searchable by breed and organ systems.
& The Listing of Inherited Disorders in Animals
(LIDA) is designed to gather, collate and disseminate
data on the prevalence of inherited disorders among
Australian dogs (34). The database is searchable by
breed group, breed, and organ systems.
& The NCBI website offers numerous databases includ-
ing Online Mendelian Inheritance in Man (OMIM), a
database of human genes and genetic disorders (12).
The identiﬁcation of speciﬁc gene mutations and gene
markers provides information on, and the ability to test for,
multiple genetic diseases. Therefore, molecular genetic testing is a
rapidly evolving science within veterinary medicine (35). Ban-
nasch and Hughes (36) compiled a list of the available
commercial tests and the laboratory contact information. Cur-
rently, there are over 100 DNA-based tests for inherited diseases
and traits in dogs. For example, a test is available to determine
the presence of MDR-1 mutations in Collies; this mutation
results in increased toxicity when these dogs are administered
certain p-glycoprotein substrates such as ivermectin (37,38).
In the future, validated microarray technology will be
available to screen dogs for polymorphisms in metabolic
enzymes in a single test. This technology already exists for
testing certain CYP polymorphisms in humans. For example,
the FDA approved AmpliChip CYP450 Test which identiﬁes
a human patient’s CYP2D6 and CYP2C19 genotype from
genomic DNA extracted from a whole blood sample (39).
BREED-RELATED DIFFERENCES
IN PHARMACOKINETICS AND PHARMACODYNAMICS
The genetic variation that exists between breeds of dogs
results in a risk of breed-related differences in the effective-
ness and toxicological responses to drugs. This potential
source of population variability needs to be considered in the
design and interpretation of studies of the canine physiology
and drug pharmacology.
A list of identiﬁed breed-speciﬁc idiosyncrasies that can
inﬂuence drug absorption and metabolism are provided in
Tables III and IV (40–54). Table III includes recognized
metabolic idiosyncrasies and Table IV includes physiologic
idiosyncrasies. Abbreviations are provided at the end of each
table.
Breed-related differences can inﬂuence drug pharmaco-
kinetics and pharmacodynamics. Therefore, there can be
discordance in the dose-response relationship across breeds.
For example, differences, such as the lower percent body fat
seen in the Greyhound, can lead to a lower than expected
volume of distribution for lipophilic compounds (43). This
lower percent body fat can result in higher serum drug
concentrations as compared to that seen in breeds with a
higher percent body fat. Accordingly, Greyhounds are
associated with a greater risk of toxicity for lipophilic
compounds.
Large breed dogs also tend to be predisposed to
sulfonamide polyarthropathy. Reports of sulfonamide ar-
thropathy have been reported in Labrador retrievers, Golden
retrievers, Great Danes, Dalmations, Giant Schnauzers,
Briards, Weimaraners, Irish setters, Flat coated retrievers,
Gordon setters, Springer spaniels, German short haired
pointers, and Airedales, with only two cases reported in smaller
dogs (one Cocker spaniel and one Pekingese) (55). This
tendency tends to be particular prevalent among Doberman
Pinschers, where protein-losing nephropathy, leukopenia, and
modest thrombocytopenia have also been observed (55). The
basis for the Doberman’s predisposition to sulfonamide toxicity
may reﬂect the limited capacity of this breed to detoxify the
hydroxylamine metabolites of the sulfonamides (56).
In another example, the size of a dog appears to
inﬂuence growth rate, vitamin D3 metabolism and circulating
levels of IGF-1 (which indirectly reﬂects the levels of growth
hormone) (57). Great Danes (GD) have a statistically
signiﬁcantly greater rate of growth as compared to Miniature
Poodles, (MP) signiﬁcantly greater plasma concentrations of
growth hormone (approximately 20 versus 7 µg/l for the GD
and MP, respectively at 7 weeks of age) and IGF-1 (ap-
proximately 400 versus 150 µg/l for the GD versus MP,
respectively at 16 weeks of age), and a signiﬁcantly lower
clearance of vitamin D3 (approximately 0.625 l/kg per day
versus 0.3 l/kg per day for the GD and MP, respectively at
19 weeks of age). GD’s also have a signiﬁcantly higher rate of
renal reabsorption of inorganic phosphate as compared to the
MP and a signiﬁcantly greater rate of bone turnover and
resorption. Furthermore, the GD has a signiﬁcantly higher
frequency of growth plate irregularities, which may be due to
higher levels of calcitonin and/or lower concentrations of
vitamin D3 metabolites (relative to the MP). It is also
noteworthy that in adult dogs, plasma IGF-1 concentrations
are reported to be related to body size (58,59) but that
intestinal calcium absorption does not appear to be correlated
with body size (although it does appear to be correlated with
dog age) (60).
Considering the potential impact of breed on drug
pharmacokinetics and pharmacodynamics, studies employing
similar protocols but different breeds can lead to inconsistent
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where new medications are being evaluated for use in dogs,
when determining appropriate medications or dosages in
veterinary practice, or when using the dog as a preclinical
species for human drug development. For example:
1. Platelet aggregation response to arachidonic acid (in
vitro assay) was highly dependent upon breed, with
some breeds having only a small proportion of
individuals exhibiting an irreversible response (e.g.,
Greyhounds and Beagles) while other breeds (Scottish
Terrier) were associated with the majority of individu-
als having an irreversible response (61). Therefore,
breed differences in platelet aggregation responses to
certain drugs may be an important consideration when
using the dog as a model for platelet-related cardio-
vascular disorders.
2. The Welsh Corgi is known to have an autosomal
recessive severe combined immunodeﬁciency. Male
Weimaraners are predisposed to a neutrophil function
defect with a primary or secondary reduction in circulat-
ing IgG (62). Affected animals of both of these breeds
Table III. Examples of Breed Related Metabolic Differences
Breed
Enzyme or Gene
Linked to Finding Genetic Finding/Metabolic Effects
Beagle CYP1A Polymorphism/genotypic variation in CYP1A2 activity (due to
differences in enzyme expression). Poor metabolizers and
extensive metabolizers result in signiﬁcant polymorphic
hydroxylation of a novel benzodiazepine (40,41)
Greyhound CYP2B11 Deﬁcient in CYP2B11. Canine CYP2B11 is responsible for
propofol hydroxylation in dogs (42,43). CYP2B11 may be
orthologue to human CYP2B6.
Mixed Breeds CYP2B11 14-fold variance in CYP2B11 activity in mixed breed dogs.
Mixed breed dogs tended to span range of Vmax seen in
Beagles (high) and Greyhounds (low) (42,43)
All breeds CYP2C CYP2C is polymorphic in dogs. Two isoforms identiﬁed—CYP2C21
in all evaluated dogs (25/25). CYP2C41 only found in 14–16%
of tested dogs. CYP2C41 appears neither breed or gender speciﬁc( 43)
Beagle CYP2D15 Signiﬁcant pharmacogenetic variation in gene encoding CYP2D15
(counterpart to human CYP2D6). Other undeﬁned CYPs may also
be involved. Signiﬁcant pharmacogenetic variation in celecoxib
metabolism in purebred Beagles. Celecoxib is primarily a CYP2D15
substrate in dogs. Extensive metabolizers (about 50% of those
tested) have an elimination half-life of 1.5–2 h. Poor metabolizers
have an elimination half-life of approximately 5 h. No gender
differences observed (45)
All breeds N-Acetyltransferase Absent in all dogs, due to loss of both N-acetyltransferase genes
in canids. N-acetylation detoxiﬁe sulfonamides, procainamide,
dapsone, isoniazid, and hydralazine. This absence may predispose
dogs to sulfonamide hypersensitivity and adverse effects from
hydralazine and dapsone (46)
Labrador Retriever TPMT Statistically signiﬁcantly higher RBC thiopurine Retriever
S-methyltransferase activity than other breeds. TPMT detoxiﬁes
azathioprine metabolites. Low TPMT activity puts animals
(or human) at risk for toxicity when using thiopurines. RBC
TPMT activity not correlated with age or gender. Nine
unequivocal haplotypes identiﬁed in dogs (47)
Cocker Spaniel TPMT Tended to have lower (but not signiﬁcant) TPMT activity as compared
to other breeds. More testing is needed (47)
Various breeds TPMT Survey of TPMT activity in 177 dogs found >ninefold range in TPMT
activity across dogs of different breeds (47)
Bedlington Terrier Murr-1 Copper storage hepatopathy due to defects in the Terrier Murr-1 gene.
Disease is autosomal recessive. Affected dogs have chronic hepatitis
resulting from a primary defect in copper excretion and abnormal
copper retention in the hepatocytes. May effect drugs metabolized
by the liver (48–50)
Boxer Sensitive to acepromazine (42)
Abbreviations:
CYP: Cytochrome P450 oxidative enzymes. For example, the nomenclature, CYP2D6 refers to the enzyme (CYP), gene family (e.g., 2)
subfamily (D), and individual gene (6)
Vmax: Maximum velocity of an enzymatic reaction
RBC: Red blood cell
TPMT: Thiopurine methyltransferase
114 Fleischer et al.are predisposed to recurrent infections and would likely
reveal reduced effectiveness of antimicrobial drugs,
especially drugs that work within white blood cells.
3. The risk of ibuprofen-related GI ulceration is low for
Labrador Retrievers but is very high for German
Shepherds (63).
4. Several surveys have been conducted to ascertain the
occurrence of spontaneous tumors in various canine
breeds (64–66). In addition, several sources provide an
overview of relative risk of developing malignancies as
a function of breed (21,67,68). Despite the absence of
detailed epidemiological data, there is a wealth of
circumstantial evidence supporting a relationship be-
tween breed and the relative risk of certain cancers.
(a) The Boxer has a signiﬁcantly greater risk of
developing malignant melanoma as compared to
other breeds. In contrast, the Chihuahua rarely
presents with malignant melanoma (64). Melano-
ma is most common in older dogs with dark
pigmented skin and accounts for between 5% and
7% of all canine skin tumors (69).
(b) In terms of the risk of developing mammary
cancers, itis sevenfold higher in intact as compared
to neutered females, and the pure-bred mammary
cancer rate is higher in each age group as
compared to cross-bred females (p<0.025) (65).
(c) Osteosarcoma is the most common type of primary
bone cancer accounting for up to 85% of tumorsthat
originate in the skeletal system. Of total canine
malignancies, osteosarcoma accounts for about 5%.
The giant breeds (for example, Great Danes,
Mastiffs, Bernese Mountain Dogs, and Irish Wolf-
hounds) are particularly susceptible. Large breeds
such as Rottweilers, Labradors, Golden Retrievers,
Shepherds, Dobermans, Weimaraners, Greyhounds
and Boxers are also at an increased risk (70,71).
5. The use of dogs in studies to assess the human carcino-
genicity potential for contraceptive steroids and other
compounds may be problematic because certain breeds
tend to naturally be more prone to malignant neoplasia
(72). Furthermore, while Beagles are concluded to be
an adequate model for testing drug carcinogenicity,
particularly for contraceptive steroids, certain strains of
Beagle may present a higher risk than others (72,73).
Differences across breeds also exist in the dose-response
relationship to anticholinergic and prokinetic compounds.
Two anticholinergic drugs (atropine and glycopyrrolate) and
Table IV. Examples of Breed Related Physiologic Differences
Breed Organ System Genetic Finding
Greyhound Cardiovascular Higher resting blood pressure and higher packed
red cell volume than other breeds (48,51)
Japanese Akita Hematologic RBCs contain more potassium than other breeds (48)
Beagle (laboratory) Hematologic Primary idiopathic hyperlipemia (familial) (48)
Beagle (laboratory) Hematologic Factor VII deﬁciency; autosomal dominant trait,
heterozygotes are asymptomatic (48)
Cairn Terrier Hematologic Lower LDL and higher HDL than larger breeds.
Total cholesterol and triglycerides did not vary
across breeds, but HDL and LDL levels were
breed-dependent (52)
Labrador Retriever Hematologic Higher LDL and lower HDL than smaller breeds (52)
Beagle (laboratory) Immune Severe combined immunodeﬁciency, X-linked trait (48)
Beagle Immune Lymphocytic thyroiditis, causing hypothyroidism
Japanese Akita CNS Narcolepsy, cataplexy, and epilepsy (48) inheritance suspected
Greyhound Endocrine Lower free T4 and total T4 than other breeds (48)
Basenji Renal Faconi syndrome; poor tubular resorption of glucose,
amino acids, and phosphate. Most affected dogs
present at 1–5 years of age with PU/PD (48)
Sighthounds Musculoskeletal Lower Vdss of lipophilic compounds (e.g., propofol) Likely
reﬂects the lower % body fat compared to other breeds (42)
Large vs Small Breeds Gastrointestinal Body size and breed related differences in small
breeds pyloric sieving, GI transit time, fecal quality,
and “leakiness” of the tight junctions (see discussion
later in this review)
Renal GFR, expressed per kg body weight, tends to be inversely
correlated to body size (53). Accordingly, plasma creatinine
values tend to be higher in large (>30 kg) as compared
to small (>10 kg) breed dogs (54)
Abbreviations:
LDL: Low density lipoprotein
HDL: High density lipoprotein
CNS: Central nervous system
PU: Polyuria
PD: Polydipsia
GI: Gastrointestinal
GFR: Glomerular ﬁltration rate
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evaluated in four Beagles and four Labrador Retrievers (74).
In Beagles, low doses of atropine [0.02 mg/kg via intramus-
cular (IM) injection] and glycopyrrolate (0.005 mg/kg by IM
injection) completely inhibited gastric motility for at least
30 min, while higher doses (0.04 and 0.01 mg/kg for atropine
and glycopyrrolate, respectively) resulted in a cessation of
activity for more than 3 h. In Labradors, the effects of
glycopyrrolate lasted at least 6-h, regardless of dose, and the
effects of atropine lasted for approximately 3-h, regardless of
dose. With respect to the prokinetic agents, the increase in
amplitude of gastric contractions of Beagles receiving a low
dose of metoclopramide (0.3 mg/kg IM) or cisapride (0.2 mg/kg
IM) was signiﬁcant, but higher doses paradoxically caused a
lesser increase in the amplitude of gastric contractions. In
Labradors, both medications,mainlyat higherdoses,resulted in
an increase in the amplitude of intestinal contraction. However,
the low dose of cisapride had no effect, and a low dose of
metoclopramide exerted only a transient effect. Cisapride did
not affect the frequency of antral contractions in either Beagles
or Labradors. In Beagles, metoclopramide resulted in a dose-
related increase in the frequency of contraction. Metoclopra-
midedidnotincreasethefrequencyofcontractioninLabradors.
BREED DIFFERENCES IN GI PHYSIOLOGY
The GI tract of large breed dogs (e.g. 60 kg) comprises
2.8% of their total body weight. In contrast, it comprises 7% of
the total body weight of small breed dogs (e.g. 5 kg) (75). There
are also marked differences in fecal moisture content where
giant breeds tend to have greater moisture content and a
higher frequency of loose stools as compared to those of small
breed dogs (76). Such breed-related differences could reﬂect
dissimilarities in GI transit time, intestinal fermentation, diet,
metabolism or drug absorption. For example, fecal quality is
softer in dogs fed canned diets as compared to those fed dry
diets, and this food-related inﬂuence on fecal consistency is
more pronounced in German Shorthair Pointers and German
Shepherds as compared to Beagles, suggesting a breed-related
difference in the way that diets are handled (77).
The relationship between breed and fecal quality could
also reﬂect a relationship between breed and GI transit time.
Using radiopaque markers (1.5 mm diameter administered in
food), 12 week old large breed puppies (e.g. Great Danes)
exhibited a signiﬁcantly longer oro-cecal transit time (OCTT;
3.4 h) as compared to small breed puppies (e.g. Miniature
Poodle, 2.5 h). The longer transit time appeared to reﬂect
both a longer gastric emptying time and a longer small
intestinal transit time between breeds (78). However, by
60 weeks of age, these breed-related differences in OCTT are
signiﬁcantly reduced (e.g. Great Dane=2.7 h; Miniature
Poodle=2.2 h) (79). Although studies involving radiopaque
markers do not demonstrate breed-related differences in
gastric transit time or small intestinal transit time of adult
dogs, investigations involving the
12C-octanoic acid breath
test (OABT) do demonstrate a correlation between body size
and gastric retention time (80). The inconsistency in study
results may reﬂect the methodologies used for estimating
gastric transit time. Estimates of emptying time are highly
correlated with particle size (81), and studies involving such
particles tend to be associated with greater lag times (gastric
retention) (82).
Mean total gastrointestinal transit time (MTT), reﬂecting
time from intake to excretion, was found to be signiﬁcantly
correlated with bodysizein adifferentstudywheretransit time
wastrackedthoughplasticbeads(2mmdiameter)containedin
food. In the latter study, MTT increased from 22 h for the
Miniature Poodle to 59 h for a Giant Schnauzer (83).
There also appears to be differences in intestinal
permeability between dog breeds. The ratio of lactulose (L)
to rhamnose (R)r e ﬂects the relative absorption occurring
across the intestinal tight junction (transcellular transport)
versus the intestinal surface area (paracellular absorption,
which occurs across the cell membrane of the enterocyte). It
was noted that marked differences in these ratios occur across
breeds, with the L/R ratio being substantially greater in the
Greyhound as compared to the Golden Retriever (84).
Breed-related differences exist in the ability for large-
sized particles to pass through the pylorus. For example, a
tetrahedron-shaped device (2 cm per arm), administered in a
capsule after an 18 hour fast, was retained in the 10 kg Beagle
for 24 h. However the device was rapidly emptied in the 35 kg
American Foxhounds (85). Therefore, the minimum restric-
tive size for a device retained by the stomach depended on
the size of the breed. This observation may be particularly
important when considering the development of gastro-
retentive devices.
WITHIN-BREED POLYMORPHISM
Breed alone may not provide sufﬁcient information
regarding genetic idiosyncrasies. For example, within strains
of purebred Beagles, there are subpopulations of fast and
slow metabolizers of celecoxib, a ﬁnding attributed to genetic
polymorphism associated largely with CYP2D15 and
CYP3A12 (86). To date, nine canine CYP isoenzymes have
been identiﬁed through cloning and sequencing. Five of these
isoenzymes have been reported as genetically polymorphic
(87–90). These include CYP1A2, CYP2C41, CYP2D15,
CYP2E1 and CYP3A12. These polymorphisms can lead to
differences in drug exposure and could result in strain-related
differences in drug responses (the differences in responses
may affect the safety and/or effectiveness of the drug).
Therefore, breed alone may not provide all the information
needed regarding relative factors and genetic traits that may
impact a study.
Congenital abnormalities can be linked to a variety of
factors including the age of parents at the time of conception,
poor nutrition, infections (viral, bacterial, or parasitic),
exposure to chemical or other environmental factors, and
genetic defects (91). Among the abnormalities of concern,
various forms of renal insufﬁciency have been linked to
genetic defects. Renal insufﬁciencies will impact the pharma-
cokinetic and toxicological assessment of drugs. Thus, even
the use of a single breed does not provide an assurance of
pharmacokinetic and pharmacodynamic homogeneity be-
tween the study subjects.
Within breeds, there can be genetic subgroups that are
associated with distinct metabolic idiosyncrasies. For example,
thePoodlecanbesubdividedintotheStandardPoodle(~25kg),
116 Fleischer et al.Miniature Poodle (~15 kg) and Toy Poodle (~5 kg). Across
these subgroups, there was a distinct size-related difference in
the circulating levels of the potent stimulator of cell replication
and DNA and RNA synthesis, IGF-1 (59). These differences in
IGF-1 levels and its release in response to IVadministration of
clonidine (10 µg/kg) were signiﬁcantly correlated with body
weight. None of these three subgroups exhibited a deﬁciency in
growth hormone (GH). This observation led to the suggestion
that the apparent GH resistance is related to differences in
hepatic endocrine activity.
CONCLUSIONS
Genetic and phenotypic differences across breeds can
inﬂuence the effect of a dose on product safety and effective-
ness. Understanding these breed differences will improve
canine population predictions (for canine drug products) and
may be of value when extrapolating toxicology data from dogs
to humans.. It will also serve to greatly assist our interpretation
of data from studies that use dogs as a model for human
therapeutics and disease. However, the amount of information
on the pharmacokinetic and pharmacodynamic differences
that can occur across breeds remains very limited.
The Animal Pharmaceutics and Technology Focus
Group of the AAPS hope to continue adding to this body
of data to provide a valuable resource for individuals
interested in exploring breed differences in dogs and how
these differences can inﬂuence drug pharmacokinetics and
pharmacodynamics. The focus group welcomes additional
information that can contribute to this evolving database. To
provide additional information or comments please contact
Dr. Marilyn Martinez at marilyn.martinez@fda.hhs.gov.
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